Jänne, Pasi A <br/><br/>
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2014 
 - 316-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0000000000000088  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Cohort Studies<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Prognosis<br/>Protein Kinase Inhibitors--pharmacokinetics<br/>Quinazolines--pharmacokinetics<br/>Quinoxalines--pharmacokinetics<br/>Safety<br/>Sulfonamides--pharmacokinetics<br/>Survival Rate<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Tissue Distribution